Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 as Adjuvant to Ramipril in CKD
NCT05942027Phase 4Recruiting
- Sponsor
- Tanta University
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of coenzyme q10 in chronic kidney disease (CKD) and hypertension (HTN) (2 arms), sponsored by Tanta University. Primary endpoints: Estimated Glomerular Filtration Rate at 6 months, Albumin-to-creatinine ratio at 6 months and 5 more. Started Jul 2023; status: recruiting.
02
Drugs
coenzyme q10
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NCT05942027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942027.